Impact ledger
Biogen Inc. (BIIB): the developments shaping its investment case
Follow the evidence affecting Biogen Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Biogen Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-14 · 4 reports
FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
Channel: Increased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Spinraza.
Bearish· 3-12m
2026-09-01
Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis
Channel: Increased competition in the multiple sclerosis market from a potentially superior oral BTK inhibitor could erode market share for existing and pipeline MS therapies.
Bearish· 1-5y
2026-09-01
Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
Channel: Increased competition in the multiple sclerosis market, particularly for oral therapies. Potential market share erosion for existing MS drugs.
Bearish· 1-5y
Event impact log
40 events mapped to BIIB since 2026-08-14. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer Data | Indirectly, as a large biotechnology company with an oncology pipeline, general positive sentiment or validation of novel therapeutic approaches in cancer could have a very minor, diffuse effect. However, Biogen's primary focus is not liver cancer or oncolytic viruses. | watch | 3-12m | 0.10 |
| 2026-09-29 | Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Priority Review Voucher | Precedent for PRV monetization and valuation. Increased market awareness of PRV value could influence valuations of companies holding or pursuing PRVs. | watch | 3-12m | 0.20 |
| 2026-09-25 | ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share | Indirect impact on sector sentiment and potential M&A landscape. A strong IPO market might encourage more private companies to stay independent longer, potentially reducing the pool of acquisition targets for larger biopharma firms, or it could validate higher valuations for innovative assets, influ | watch | 3-12m | 0.20 |
| 2026-09-24 | Ionis reports positive Phase III trial results for partnered drugs in ALS and kidney disease | Potential competitive pressure in the ALS market, depending on ulefnersen's efficacy and safety profile relative to existing or developing treatments. | watch | 3-12m | 0.40 |
| 2026-09-24 | Ionis Announces Positive Phase III Trials for ALS and IgA Nephropathy Therapies | Indirect competitive pressure in the ALS treatment market, particularly for FUS-ALS. | watch | 3-12m | 0.30 |
| 2026-09-24 | Ionis Announces Positive Phase III Results for Partnered FUS-ALS and IgAN Programs | Potential competitive pressure in the ALS treatment market. While FUS-ALS is a specific subtype, any new ALS therapy could shift market dynamics. | watch | 3-12m | 0.30 |
| 2026-09-23 | Roche to Acquire Ionis Pharmaceuticals, Inc. | Increased M&A activity in the neurology/rare disease space, potentially increasing valuation for similar assets or making future acquisitions more competitive. | watch | 3-12m | 0.30 |
| 2026-09-21 | Ionis Plunges Over 40% Following Clinical Setbacks in Pelacarsen and Eplontersen | Second-order effect from partnership revenue loss for eplontersen, though diversified pipeline mitigates overall impact. | Bearish | 3-12m | 0.20 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | Indirect impact through partnership agreements and potential milestone payments or royalty streams from Ionis's ASO assets. | watch | 3-12m | 0.20 |
| 2026-09-21 | Ionis slides over 40% year-to-date following late-stage clinical setbacks | Eplontersen, another drug with setbacks, is partnered with Biogen. Similar to AZN, this impacts potential future revenue and milestone payments. | Bearish | 1-3m | 0.30 |
| 2026-09-21 | Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks | Partnership risk. Biogen is a partner for eplontersen. Setbacks for this drug could reduce future royalty/milestone payments. | Bearish | 3-12m | 0.20 |
| 2026-09-21 | Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks | Loss of potential future milestone payments and royalties from eplontersen, which was partnered with Biogen. Reputational risk for partnership efficacy. | Bearish | 3-12m | 0.30 |
| 2026-09-18 | Electra Therapeutics, Inc. IPO — $350M | Increased investor attention and capital allocation towards the broader biotechnology sector, potentially leading to re-evaluation of comparable companies. | watch | 1-3m | 0.30 |
| 2026-09-17 | Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Telomir-Zn Preclinical Research in AMD | Potential long-term competitive threat in the AMD market, though highly speculative at preclinical stage. | watch | 1-5y | 0.10 |
| 2026-09-17 | Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways | Increased investor interest in companies with strong neuroscience and rare disease pipelines, potential for future pipeline expansion or partnerships in cardiovascular diseases. | Bullish | 1-3m | 0.60 |
| 2026-09-16 | Acumen Pharmaceuticals Projects Cash Runway into Early 2027 | Competitive landscape in Alzheimer's disease. Acumen's pipeline progress (sabirnetug) could eventually impact market share or pricing power for existing or future Alzheimer's treatments. | watch | 3-12m | 0.20 |
| 2026-09-16 | Acumen Pharmaceuticals, Inc. Provides Strategic Pipeline Update and Cash Runway Guidance | Indirect market sentiment and competitive landscape in Alzheimer's disease treatments. | watch | 3-12m | 0.20 |
| 2026-09-16 | Acumen Pharmaceuticals, Inc. Outlines Strategic Goals and Cash Runway into Early 2027 | Indirect competitive landscape dynamics in Alzheimer's disease. Similar to LLY, Biogen's AD portfolio (Aduhelm, Leqembi) could be marginally affected by broader market sentiment or competitive developments. | watch | 3-12m | 0.10 |
| 2026-09-16 | Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy | Increased investor preference for innovative oncology platforms like mRNA, potentially diverting capital from companies with less novel or slower-progressing pipelines. | Bearish | 3-12m | 0.30 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potential erosion of market share for Spinraza. | Bearish | 3-12m | 0.60 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Increased competition in the Spinal Muscular Atrophy (SMA) market. Isembyld is positioned as a combination therapy, potentially impacting market share or pricing power of existing SMA treatments. | mixed | 3-12m | 0.40 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies. | mixed | 3-12m | 0.40 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Potential competitive pressure or market expansion in the SMA treatment landscape. | watch | 3-12m | 0.40 |
| 2026-09-13 | Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1 | While not a direct competitor in all immunology areas, LLY's M&A strategy for pipeline expansion (e.g., DICE, Morphic) highlights the value of innovative early-stage assets, potentially increasing M&A competition or valuation expectations for smaller biotechs. | watch | 3-12m | 0.20 |
| 2026-09-12 | Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A Pipeline | Eli Lilly's successful M&A strategy in immunology could signal a more aggressive M&A environment, potentially increasing acquisition targets' valuations or creating more formidable competitors for Biogen's pipeline assets. | watch | 1-5y | 0.30 |
| 2026-09-12 | Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A | While not directly competing in all immunology sub-segments, the success of M&A in immunology by a peer like LLY could influence investor sentiment towards biotech M&A and pipeline valuation, especially for companies with immunology assets. | watch | 3-12m | 0.20 |
| 2026-09-12 | Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assets | Eli Lilly's strategic M&A for non-GLP-1 clinical pipeline optionality, particularly in areas like neuroscience or rare diseases, could signal broader industry trends that might eventually impact Biogen's focus areas, though the direct impact is not immediate. | watch | 1-5y | 0.40 |
| 2026-09-12 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Increased competition in the SMA treatment market, potential for market share shift or pricing pressure. | watch | 3-12m | 0.40 |
| 2026-09-12 | FDA Approves Isembyld for Spinal Muscular Atrophy | Increased competition in the SMA treatment market, potential erosion of market share for existing therapies. | Bearish | 1-3m | 0.60 |
| 2026-09-12 | Eli Lilly immunology division generates $2.6B in H1 revenue (+9% YoY) via M&A push | Increased M&A activity and competition in immunology could lead to higher R&D costs or pressure on pipeline assets for companies with immunology exposure. | watch | 1-5y | 0.30 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld for spinal muscular atrophy | Increased competition in the Spinal Muscular Atrophy (SMA) market, potentially impacting market share and pricing power for existing therapies. | mixed | 3-12m | 0.40 |
| 2026-09-03 | NEJM publishes Revolution Medicines Phase 1/2 data showing 42% ORR in NSCLC | Potential for future M&A activity or partnership interest in oncology assets. | watch | 1-5y | 0.10 |
| 2026-09-01 | Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials | Increased competition for existing and pipeline MS drugs, potential market share erosion. | Bearish | 1-5y | 0.60 |
| 2026-09-01 | Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial | Increased competition in the multiple sclerosis market, particularly for oral therapies. Potential market share erosion for existing MS drugs. | Bearish | 1-5y | 0.60 |
| 2026-09-01 | Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis | Increased competition in the multiple sclerosis market from a potentially superior oral BTK inhibitor could erode market share for existing and pipeline MS therapies. | Bearish | 1-5y | 0.60 |
| 2026-08-28 | Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim | Increased competition in the CNS therapeutic area, particularly for neurological disorders. | watch | 3-12m | 0.30 |
| 2026-08-28 | Biohaven Signs $795M Licensing Deal with SK Biopharm for Opakalim | Similar to Moderna, as a large-cap biotech with an active pipeline and history of M&A/licensing, positive sector sentiment from such deals could provide a minor uplift or reinforce valuation assumptions. | watch | 1-3m | 0.20 |
| 2026-08-26 | FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor | Indirect sector sentiment, potential for M&A activity in biotech, or strategic shifts in R&D focus for companies with significant cash reserves. | watch | 3-12m | 0.20 |
| 2026-08-26 | Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms | Increased competition in neurodegenerative disease space, potential for new therapeutic approaches to influence R&D strategies. | watch | 3-12m | 0.60 |
| 2026-08-14 | Replimune Group, Inc. Follow-On — $150M | Potential indirect sentiment spillover within the oncology/biotech sector. | watch | 1-3m | 0.20 |
Continue this research
Build your Biogen Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the BIIB entity page →